|
MechanismPDE5A inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date12 Nov 2002 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Callitas Therapeutics, Inc.
0 Patents (Medical) associated with Callitas Therapeutics, Inc.
100 Deals associated with Callitas Therapeutics, Inc.
100 Translational Medicine associated with Callitas Therapeutics, Inc.